<DOC>
	<DOC>NCT02551861</DOC>
	<brief_summary>The purpose of this study is to determine if 8 weeks of Daclatasvir plus Sofosbuvir with or without Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients without advanced fibrosis or liver cirrhosis who have never been treated previously.</brief_summary>
	<brief_title>A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Na√Øve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Genotype 3 HCV RNA &lt; 2000000 IU/mL Never taken HCV medication Absence of advanced fibrosis or cirrhosis Body mass index (BMI) 1840 kg/m^2 Infection with HCV other than genotype 3 (GT3); Mixed infections of any genotype Previously taken HCV medication Liver Cirrhosis Evidence of decompensated liver disease HIV/ hepatitis B virus (HBV) coinfection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>